Cellectis SA (ALCLS) Price & Analysis

Q: What was Cellectis SA’s price range in the past 12 months?

Cellectis SA lowest stock price was €1.01 and its highest was €4.84 in the past 12 months.

Q: What is Cellectis SA’s market cap?

Cellectis SA’s market cap is €296.30M.

Q: When is Cellectis SA’s upcoming earnings report date?

Cellectis SA’s upcoming earnings report date is Mar 11, 2026 which is in 84 days.

Q: How were Cellectis SA’s earnings last quarter?

Cellectis SA released its earnings results on Nov 07, 2025. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of -€0.198 by €0.207.

Q: Is Cellectis SA overvalued?

According to Wall Street analysts Cellectis SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Cellectis SA pay dividends?

Cellectis SA does not currently pay dividends.

Q: What is Cellectis SA’s EPS estimate?

Cellectis SA’s EPS estimate is -0.27.

Q: How many shares outstanding does Cellectis SA have?

Cellectis SA has 72,093,636 shares outstanding.

Q: What happened to Cellectis SA’s price movement after its last earnings report?

Cellectis SA reported an EPS of €0.009 in its last earnings report, beating expectations of -€0.198. Following the earnings report the stock price went up 12.238%.

Q: Which hedge fund is a major shareholder of Cellectis SA?

Currently, no hedge funds are holding shares in FR:ALCLS

Compare

2 Followers

ALCLS Stock Chart & Stats

€3.43

-€0.02(-1.32%)

At close: Jan 09 4:00 PM EST

€3.43

-€0.02(-1.32%)

Day’s Range― - ―

52-Week Range€1.01 - €4.84

Previous CloseN/A

Volume10.86K

Average Volume (3M)852.48K

Market Cap

€296.30M

Enterprise Value€56.58M

Total Cash (Recent Filing)€52.24M

Total Debt (Recent Filing)€37.58M

Price to Earnings (P/E)―

Beta0.61

Next Earnings

Mar 11, 2026

EPS Estimate

-0.27

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)<0.01

Shares Outstanding72,093,636

10 Day Avg. Volume1,338,181

30 Day Avg. Volume852,477

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)1.16

Price to Sales (P/S)3.65

P/FCF Ratio7.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Cellectis SA News

Allogene Therapeutics says favorable result for Servier in Cellectis arbitration

Allogene Therapeutics (ALLO) noted the favorable outcome for Servier in its arbitration with Cellectis (CLLS) as it relates...

1d ago

ALLO

CLLS

Cellectis announces arbitral decision in dispute with Servier

Cellectis (CLLS) announces that the Arbitral Tribunal has issued its decision in the arbitration proceedings against Les Laboratoires...

1d ago

CLLS

Cautious Hold Rating for Cellectis SA Amid Key Clinical and Financial Milestones

JonesTrading analyst Soumit Roy has maintained their neutral stance on CLLS stock, giving a Hold rating today. Soumit...

1M ago

CLLS

Cellectis reports Q3 adjusted EPS 2c vs (22c) last year

Reports Q3 revenue $35.17M vs 16.2M last year. “We are proud of the promising data from our core...

1M ago

CLLS

CMVLF Upcoming Earnings Report: What to Expect?

Cellectis SA (CMVLF) is scheduled to report 3rd quarter earnings on 11/07/2025, after the market closes. Regarding Q3...

1M ago

Cellectis to present development update for eti-cel at ASH 2025

Cellectis (CLLS) announced the acceptance of two abstracts for poster presentation at the American Society of Hematology, ASH,...

1M ago

CLLS

Cellectis price target raised to $4 from $3 at Wells Fargo

Wells Fargo analyst Nick Abbott raised the firm’s price target on Cellectis (CLLS) to $4 from $3 and...

2M ago

CLLS

Cellectis price target raised to $8 from $4 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Cellectis (CLLS) to $8 from $4 and keeps...

2M ago

CLLS

Cellectis SA’s Promising Study on UCART20x22 for B-Cell Non-Hodgkin Lymphoma

Cellectis SA (($CMVLF)) announced an update on their ongoing clinical study. Study Overview: The clinical study titled Open-label...

3M ago

CMVLF

Cellectis SA: Hold Rating Amid Upcoming Data Presentations and Financial Considerations

JonesTrading analyst Soumit Roy has maintained their neutral stance on CLLS stock, giving a Hold rating on August...

4M ago

CLLS

Cellectis S.A. Advances UCART123 Clinical Study in AML Treatment

Cellectis S.A. (($CLLS)), Cellectis SA (($CMVLF)) announced an update on their ongoing clinical study. In a recent update,...

4M ago

CLLS

Cellectis Reports Q2 2025 Results and Strategic Updates

Cellectis SA ( ($CMVLF) ) has released its Q2 earnings. Here is a breakdown of the information Cellectis...

4M ago

CMVLF Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Cellectis SA (CMVLF) is scheduled to report 2nd quarter earnings on 08/04/2025, after the market closes. Regarding Q2...

5M ago

Cellectis files $200M mixed securities shelf

16:20 EDT Cellectis (CLLS) files $200M mixed securities shelf Published first on TheFly – the ultimate source for...

6M ago

CLLS

ALCLS FAQ

What was Cellectis SA’s price range in the past 12 months?

Cellectis SA lowest stock price was €1.01 and its highest was €4.84 in the past 12 months.

What is Cellectis SA’s market cap?

Cellectis SA’s market cap is €296.30M.

When is Cellectis SA’s upcoming earnings report date?

Cellectis SA’s upcoming earnings report date is Mar 11, 2026 which is in 84 days.

How were Cellectis SA’s earnings last quarter?

Cellectis SA released its earnings results on Nov 07, 2025. The company reported €0.009 earnings per share for the quarter, beating the consensus estimate of -€0.198 by €0.207.

Is Cellectis SA overvalued?

According to Wall Street analysts Cellectis SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cellectis SA pay dividends?

Cellectis SA does not currently pay dividends.

What is Cellectis SA’s EPS estimate?

Cellectis SA’s EPS estimate is -0.27.

How many shares outstanding does Cellectis SA have?

Cellectis SA has 72,093,636 shares outstanding.

What happened to Cellectis SA’s price movement after its last earnings report?

Cellectis SA reported an EPS of €0.009 in its last earnings report, beating expectations of -€0.198. Following the earnings report the stock price went up 12.238%.

Which hedge fund is a major shareholder of Cellectis SA?

Currently, no hedge funds are holding shares in FR:ALCLS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cellectis SA

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Cellectis SA (ALCLS) Earnings & Revenues

Historic Earnings Reports

ALCLS Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.View all FR:ALCLS earnings summaries